Endocrinology diabetes and metabolism impact factor
These studies included almost 3 million adults from around the world, yet the results were remarkably consistent, the authors of the analysis noted. Several factors may account for this finding, Flegal added. For the study, Flegal's team collected data on more than 2.
The researchers looked at the participants' body mass index, or BMI, which is a measurement of body fat that takes into account a person's height and weight. Pooling the data from all endocrinology diabetes and metabolism impact factor studies, the researchers found that compared with normal weight people, overweight people had a 6 percent lower risk of death.
Obese people, however, had an 18 percent higher risk of death.
For those who were the least obese, the risk of death was 5 percent lower than for normal weight people, but for those who were the most obese the risk of death was 29 percent higher, the findings revealed. While the study found an association between weight and premature death risk, it did not prove a cause-and-effect relationship.
Indeed, one expert cautioned that body weight alone cannot predict health and the risk of death. William Cefalu, chief and professor of the section of endocrinology, diabetes and metabolism at Louisiana State University and co-author of an accompanying journal editorial.
Another expert agreed and added that the issues around body weight are more complicated than this study suggests. There is a case to be made fekély a lábak diabetes mellitus fotó a body mass index in what is now considered the overweight range might be redefined as normal, Katz said.
This study, however, looks only at death, not chronic köszvény cukorbetegség conditions, Katz noted. This study would be blind to such effects," he said.
PubMed: Szakterületek: The global epidemic of type 2 diabetes affects women and men equally; however, the relative impact on the cardiovascular CV system appears greater for women than men when compared with peers without diabetes. Furthermore, women are often under-represented in CV outcome trials, resulting in less certainty about the impact of CV prevention therapies across the sexes. Here we report a secondary analysis of the trial to determine the relative effects of empagliflozin in women vs men. Individuals were randomised to receive empagliflozin 10 mg or 25 mg, or placebo once daily in addition to standard of care, and followed.
Katz also noted the trends in obesity may be tipping the scale toward increased risk of dying. This study suggests being overweight and remaining so might offer health advantages, "but moving from overweight to obese, and from obese to more obese, is a serious peril and many in the population are doing exactly that," Katz pointed out.
More information For more on obesity, visit the U. National Library of Medicine.